Barclays
TERN

Barclays’s Terns Pharmaceuticals TERN Stock Holding History

Barclays’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.3M Buy
669,601
+498,415
+291% +$20.5M 0.01% 858
2025
Q4 		$6.92M Buy
171,186
+40,795
+31% +$943K ﹤0.01% 1971
2025
Q3 		$979K Sell
130,391
-114,246
-47% -$729K ﹤0.01% 3379
2025
Q2 		$912K Sell
244,637
-408,400
-63% -$1.28M ﹤0.01% 3401
2025
Q1 		$1.8M Sell
653,037
-51,334
-7% -$210K ﹤0.01% 2711
2024
Q4 		$3.9M Buy
704,371
+609,469
+642% +$4.13M ﹤0.01% 2379
2024
Q3 		$791K Sell
94,902
-100,540
-51% -$827K ﹤0.01% 3510
2024
Q2 		$1.33M Sell
195,442
-52,862
-21% -$320K ﹤0.01% 2415
2024
Q1 		$1.63M Buy
248,304
+163,722
+194% +$1.07M ﹤0.01% 2740
2023
Q4 		$549K Buy
84,582
+30,255
+56% +$160K ﹤0.01% 3817
2023
Q3 		$273K Sell
54,327
-208,591
-79% -$1.32M ﹤0.01% 3134
2023
Q2 		$2.3M Sell
262,918
-271,842
-51% -$3.17M ﹤0.01% 1801
2023
Q1 		$6.33M Buy
534,760
+18,021
+3% +$172K ﹤0.01% 1405
2022
Q4 		$5.26M Sell
516,739
-142,359
-22% -$948K ﹤0.01% 1584
2022
Q3 		$3.88M Buy
659,098
+645,973
+4,922% +$2.4M ﹤0.01% 1320
2022
Q2 		$33K Sell
13,125
-2,227
-15% -$4.45K ﹤0.01% 4207
2022
Q1 		$46K Buy
+15,352
New +$65.5K ﹤0.01% 4151

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Barclays's TERN Position: Q1 2026 in Review

Barclays increased its Terns Pharmaceuticals (TERN) stake by 291% in Q1 2026, buying an estimated $20.5M and bringing the position to 669,601 shares worth $35.3M. The position accounts for 0.01% of the portfolio, ranked #858.

Barclays first reported a position in TERN in Q1 2022 and has held it in 17 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Barclays held 669,601 shares of Terns Pharmaceuticals worth $35.3M as of Q1 2026.
  • Barclays bought 498,415 Terns Pharmaceuticals shares in Q1 2026, an estimated $20.5M.
  • Terns Pharmaceuticals made up 0.01% of Barclays's portfolio in Q1 2026, its #858 holding.
  • Barclays first reported a position in Terns Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.